Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Apatinib vs Paclitaxel + Cisplatin/Carboplatin + Bevacizumab in First-line Cervical Cancer
NCT04974944Phase 2Terminated
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jul 2021
- Primary completion
- Jan 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of camrelizumab and Rivoceranib in Cervical Cancer (CC) (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Progression-Free Survival up to 36 months. Started Jul 2021; status: terminated.
02
Drugs
camrelizumabRivoceranib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04974944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04974944.